Boston Family Office LLC raised its holdings in Celgene Co. (NASDAQ:CELG) by 0.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 136,085 shares of the biopharmaceutical company’s stock after buying an additional 847 shares during the quarter. Celgene makes up approximately 1.6% of Boston Family Office LLC’s holdings, making the stock its 14th largest holding. Boston Family Office LLC’s holdings in Celgene were worth $14,202,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other institutional investors and hedge funds have also bought and sold shares of CELG. Arcadia Investment Management Corp MI boosted its holdings in Celgene by 118.7% in the 3rd quarter. Arcadia Investment Management Corp MI now owns 737 shares of the biopharmaceutical company’s stock worth $107,000 after acquiring an additional 400 shares during the period. Robecosam AG acquired a new stake in shares of Celgene during the 3rd quarter valued at approximately $114,000. Guidant Wealth Advisors acquired a new stake in shares of Celgene during the 3rd quarter valued at approximately $119,000. Capital Bank & Trust Co raised its position in shares of Celgene by 166.8% during the 3rd quarter. Capital Bank & Trust Co now owns 827 shares of the biopharmaceutical company’s stock valued at $121,000 after acquiring an additional 517 shares in the last quarter. Finally, Fusion Family Wealth LLC acquired a new stake in shares of Celgene during the 4th quarter valued at approximately $136,000. Institutional investors own 78.63% of the company’s stock.
Shares of Celgene stock traded down $1.89 during midday trading on Friday, hitting $86.95. 6,683,406 shares of the company were exchanged, compared to its average volume of 7,531,407. The company has a debt-to-equity ratio of 2.29, a current ratio of 4.99 and a quick ratio of 4.80. The company has a market capitalization of $65,401.70, a PE ratio of 12.71, a price-to-earnings-growth ratio of 0.58 and a beta of 1.49. Celgene Co. has a 52 week low of $84.25 and a 52 week high of $147.17.
Celgene (NASDAQ:CELG) last issued its quarterly earnings data on Thursday, January 25th. The biopharmaceutical company reported $1.87 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.78 by $0.09. Celgene had a return on equity of 67.50% and a net margin of 22.38%. The firm had revenue of $3.48 billion during the quarter, compared to the consensus estimate of $3.46 billion. During the same quarter in the previous year, the company posted $1.61 EPS. The business’s revenue for the quarter was up 16.9% compared to the same quarter last year. equities analysts anticipate that Celgene Co. will post 7.66 earnings per share for the current fiscal year.
Celgene announced that its board has initiated a stock repurchase program on Wednesday, February 14th that authorizes the company to buyback $5.00 billion in outstanding shares. This buyback authorization authorizes the biopharmaceutical company to buy shares of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s board believes its stock is undervalued.
Several brokerages have weighed in on CELG. Credit Suisse Group set a $128.00 target price on Celgene and gave the stock a “buy” rating in a research report on Tuesday, December 12th. Vetr cut Celgene from a “strong-buy” rating to a “buy” rating and set a $121.72 price target for the company. in a research note on Tuesday, December 12th. Oppenheimer set a $166.00 price target on Celgene and gave the stock a “buy” rating in a research note on Thursday, December 14th. Leerink Swann reaffirmed a “buy” rating and set a $120.00 target price on shares of Celgene in a research note on Wednesday, December 13th. Finally, Stifel Nicolaus decreased their target price on Celgene from $149.00 to $130.00 and set a “buy” rating for the company in a research note on Friday, December 22nd. Three investment analysts have rated the stock with a sell rating, twelve have given a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $127.68.
In other news, Director Ernest Mario sold 13,370 shares of the business’s stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $94.49, for a total value of $1,263,331.30. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Gilla Kaplan sold 9,250 shares of the business’s stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $95.99, for a total value of $887,907.50. Following the completion of the sale, the director now owns 94,801 shares in the company, valued at $9,099,947.99. The disclosure for this sale can be found here. Over the last three months, insiders sold 41,120 shares of company stock valued at $3,879,509. Insiders own 0.95% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This article was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright law. The correct version of this article can be read at https://www.dispatchtribunal.com/2018/04/08/boston-family-office-llc-boosts-holdings-in-celgene-co-celg.html.
Celgene Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.